Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluticasone Propionate DPI Dose-Ranging in Persistent Asthma
NCT01479621Phase 2Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Jan 2012
- Primary completion
- Jul 2013
- Modality
- Orthosteric Ligands
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial of fluticasone propionate nasal spray in asthma (6 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Change From Baseline In Trough (Morning Predose And Pre-Rescue Bronchodilator) Forced Expiratory Volume In 1 Second (FEV1) at 12 weeks. Started Jan 2012; status: completed.
02
Drugs
fluticasone propionate nasal spray
03
Conditions
asthma
Beyond the preview
Go deeper on NCT01479621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01479621.